title: Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the Bayesian least-squares method.
abstract: Bayesian estimation enables the individual pharmacokinetic parameters of the medication administrated to be estimated using only a few blood concentrations. Due to wide inter-individual variability in the pharmacokinetics of methotrexate (MTX), the concentration of MTX needs to be frequently determined during high-dose MTX therapy in order to prevent toxic adverse events. To apply the benefits of Bayesian estimation to cases treated with this therapy, we attempted to develop an estimation method using the Bayesian least-squares method, which is commonly used for therapeutic monitoring in a clinical setting. Because this method hypothesizes independency among population pharmacokinetic parameters, we focused on correlations among population pharmacokinetic parameters used to estimate individual parameters. A two-compartment model adequately described the observed concentration of MTX. The individual pharmacokinetic parameters of MTX were estimated in 57 cases using the maximum likelihood method. Among the available parameters accounting for a 2-compartment model, V1, k10, k12, and k21 were found to be the combination showing the weakest correlations, which indicated that this combination was best suited to the Bayesian least-squares method. Using this combination of population pharmacokinetic parameters, Bayesian estimation provided an accurate estimation of individual parameters. In addition, we demonstrated that the degree of correlation among population pharmacokinetic parameters used in the estimation affected the precision of the estimates. This result highlights the necessity of assessing correlations among the population pharmacokinetic parameters used in the Bayesian least-squares method.
authors.affiliation: Department of Pharmacy, Kagawa University Hospital.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Watanabe
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Fukuoka
authors.forename: Toshiki
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Kazunori
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Takahiro
authors.initials: T
authors.lastname: Motoki
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Shinji
authors.initials: S
authors.lastname: Kosaka
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Houchi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001499:Bayes Theorem; D001859:Bone Neoplasms / Q000188:drug therapy; D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016018:Least-Squares Analysis; D008223:Lymphoma / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008875:Middle Aged; D015233:Models, Statistical; D012516:Osteosarcoma / Q000188:drug therapy; D066230:Patient-Specific Modeling; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D008727:Methotrexate